Comparative Pharmacology
Head-to-head clinical analysis: DENTIPATCH versus LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENTIPATCH versus LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER.
DENTIPATCH vs LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses. It exhibits antiarrhythmic activity by suppressing automaticity and conduction in cardiac tissues.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
Antiarrhythmic: 1-1.5 mg/kg IV bolus, may repeat 0.5-0.75 mg/kg in 5-10 minutes; maximum total 3 mg/kg. Followed by continuous IV infusion 1-4 mg/min. Local anesthesia: maximum 4.5 mg/kg (300 mg) without epinephrine; 7 mg/kg (500 mg) with epinephrine.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Terminal elimination half-life: 1.5–2 hours (normal cardiac output and hepatic function). Prolonged in heart failure (up to 10 hours), hepatic disease (up to 5–15 hours), and with continuous infusion (due to saturable metabolism).
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Renal: ~90% as metabolites (including monoethylglycinexylidide [MEGX] and glycinexylidide [GX]) and ~10% unchanged. Biliary/fecal: <3%.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)